The Transition Test: When Screen Persistence Meets Filing Evidence

The same continuity process produced five different filing-evidence outcomes: one defense-AI commercialization test, one merger-completion story, one regulatory-execution case, one recovery-after-stress case, and one operating-quality improvement case.

MARKET TIDE WEEKLY TUESDAY EDITION - August 18, 2026

Public version note: This public edition includes the three public Tuesday picks: IMXI, ZNTL, and TKNO. Subscriber-only sections on SPAI and KRMD are withheld from the public version. KRMD is also the confirmed Thursday Deep Dive selection, with the detailed Deep Dive analysis reserved for subscribers.

The screen found persistence. The filings reveal the test. This week’s Tuesday Edition is not built around one sector, one catalyst, or one type of company. It is built around a more disciplined question: when a name keeps appearing in the continuity process, do the filings show real transition or just market noise?

The public slate focuses on three filing-backed transition cases: IMXI, ZNTL, and TKNO. Together, they show how continuity can point to very different kinds of evidence — a merger-completion setup, a regulatory-execution story, and an operating recovery after financing stress.

Public Thesis

Continuity alone is not conviction. A repeat screen signal only becomes useful when the filing record explains what the market is actually rewarding, questioning, or waiting to confirm. In this public version, the key test is whether IMXI, ZNTL, and TKNO each have enough filing-backed evidence to justify continued monitoring.

IMXI: From Operating Pick to Merger-Completion Story

IMXI began as a mature remittance and payments operator, but the filings shifted the setup. Standalone transaction trends softened, revenue and earnings came under pressure, and the company moved into a transaction-completion frame after Western Union agreed to acquire Intermex for $16.00 per share in cash.

The public read is straightforward: IMXI is no longer mainly a standalone remittance-growth question. It is a closing-risk question. Shareholder approval and HSR clearance improved the transaction path, but remaining regulatory and money-transmitter licensing approvals still matter. If the deal closes on the agreed cash terms, the thesis resolves one way. If it does not, investors have to reassess IMXI against a weaker standalone operating backdrop.

ZNTL: Regulatory Execution Replaces Broad Biotech Optionality

ZNTL is the regulatory-execution case. The filing stack narrows the company around azenosertib, Cyclin E1-positive platinum-resistant ovarian cancer, DENALI, and ASPENOVA. The story is no longer broad biotech optionality; it is whether one focused clinical-regulatory pathway can deliver enough evidence to support the next stage of development.

The public version should treat ZNTL as a high-risk but clearly defined catalyst story. Dose selection, DENALI expansion, and ASPENOVA activation improved the execution frame, but the company remains pre-commercial, cash-consuming, and highly dependent on azenosertib. That is why the filing read supports conventional RCP-II biotech risk rather than a cleaner operating-quality classification.

TKNO: Recovery After Financing Stress

TKNO gives the public edition its recovery case. The company’s filing history includes real stress markers: ATM capacity, lender dependence, covenant pressure, waivers, amendments, and a March 2025 refinancing. Those details keep the risk classification elevated.

The transition is that recent filings show operating improvement rather than renewed financing stress. Revenue growth returned, gross margin improved, losses narrowed, cash burn moderated, and guidance improved. TKNO is not clean in the way KRMD is clean, but it is a useful public example of a company trying to recover from financing-stress history through operating execution.

Subscriber-Only Additions

Two additional Tuesday names are reserved for subscribers. SPAI is withheld because the full filing-backed defense-AI commercialization case requires more detail on 2025 recapitalization, dilution history, government-award cadence, and proof-of-repeatability risk. KRMD is withheld because it is the highest-quality operating-leverage case in the slate and has been confirmed as the Thursday Deep Dive selection.

The public takeaway is that continuity is useful only when filings explain what kind of transition is underway. IMXI tests transaction completion. ZNTL tests regulatory execution. TKNO tests recovery after financing stress. Subscribers receive the full five-name version, including SPAI and KRMD, with KRMD continuing into the Thursday Deep Dive.

Public CTA

If this public Tuesday Edition helped you see why repeat signals need filing confirmation, subscribe to Market Tide Weekly for the full five-name version, including SPAI and KRMD. Subscribers receive the withheld diligence layer, the full filing-backed transition notes, and the Thursday Deep Dive follow-through.

Thursday Deep Dive Preview

Thursday’s confirmed Deep Dive pick is KRMD. The public Tuesday version withholds the detailed KRMD analysis, but the reason for the selection is clear: KRMD is the slate’s strongest operating-leverage and self-funded-growth test. The Deep Dive will examine whether revenue growth, margin recovery, improved credit terms, manufacturing scale, and positive quarterly profitability are durable enough to support a cleaner small-cap med-tech thesis.

Subscriber teaser: The subscriber version will include the withheld KRMD filing stack, operating-metric breakdown, credit-facility read-through, manufacturing-contract implications, RCP-I evidence, and monitoring checklist for the next filing cycle.

Public Disclosure

This public article is for informational and educational purposes only and is not investment advice, a recommendation, or an offer to buy or sell any security. Market Tide Weekly uses filing-based research and continuity data, but all investing involves risk. Readers should conduct their own due diligence and consult a qualified financial professional before making investment decisions.

SPAI Works Cited

Safe Pro Group Inc. Form 10-K for the Fiscal Year Ended December 31, 2025. U.S. Securities and Exchange Commission, 31 Mar. 2026, https://www.sec.gov/Archives/edgar/data/2011208/000149315226014181/form10-k.htm.

Safe Pro Group Inc. Form 10-Q for the Quarterly Period Ended March 31, 2026. U.S. Securities and Exchange Commission, 15 May 2026, https://www.sec.gov/Archives/edgar/data/2011208/000149315226023469/form10-q.htm.

Safe Pro Group Inc. Form 8-K. U.S. Securities and Exchange Commission, 2 June 2026, https://www.sec.gov/Archives/edgar/data/2011208/000149315226026778/form8-k.htm.

Safe Pro Group Inc. Exhibit 99.1 to Form 8-K. U.S. Securities and Exchange Commission, 2 June 2026, https://www.sec.gov/Archives/edgar/data/2011208/000149315226026778/ex99-1.htm.

Safe Pro Group Inc. Form 8-K. U.S. Securities and Exchange Commission, 23 June 2026, https://www.sec.gov/Archives/edgar/data/2011208/000149315226029775/form8-k.htm.

Safe Pro Group Inc. Exhibit 99.1 to Form 8-K. U.S. Securities and Exchange Commission, 23 June 2026, https://www.sec.gov/Archives/edgar/data/2011208/000149315226029775/ex99-1.htm.

Safe Pro Group Inc. Form 8-K. U.S. Securities and Exchange Commission, 3 Aug. 2026, https://www.sec.gov/Archives/edgar/data/2011208/000149315226035761/form8-k.htm.

Safe Pro Group Inc. Exhibit 99.1 to Form 8-K. U.S. Securities and Exchange Commission, 3 Aug. 2026, https://www.sec.gov/Archives/edgar/data/2011208/000149315226035761/ex99-1.htm.

Safe Pro Group Inc. Form 8-K. U.S. Securities and Exchange Commission, 6 Aug. 2026, https://www.sec.gov/Archives/edgar/data/2011208/000149315226036259/form8-k.htm.

Safe Pro Group Inc. Exhibit 99.1 to Form 8-K. U.S. Securities and Exchange Commission, 6 Aug. 2026, https://www.sec.gov/Archives/edgar/data/2011208/000149315226036259/ex99-1.htm.

Safe Pro Group Inc. Exhibit 99.1 to Form 8-K. U.S. Securities and Exchange Commission, 14 Aug. 2026, https://www.sec.gov/Archives/edgar/data/2011208/000149315226038010/ex99-1.htm.

Safe Pro Group Inc. Form 10-Q for the Quarterly Period Ended June 30, 2026. U.S. Securities and Exchange Commission, 14 Aug. 2026, https://www.sec.gov/Archives/edgar/data/2011208/000149315226038289/form10-q.htm.

IMXI Works Cited

International Money Express, Inc. Form 10-K for the Fiscal Year Ended December 31, 2024. U.S. Securities and Exchange Commission, Feb. 2025, https://www.sec.gov/Archives/edgar/data/1683695/000168369525000030/imxi-20241231.htm.

International Money Express, Inc. Form 10-Q for the Quarterly Period Ended March 31, 2025. U.S. Securities and Exchange Commission, 2025, https://www.sec.gov/Archives/edgar/data/1683695/000168369525000063/imxi-20250331.htm.

International Money Express, Inc. Agreement and Plan of Merger. U.S. Securities and Exchange Commission, 10 Aug. 2025, https://www.sec.gov/Archives/edgar/data/1683695/000114036125029957/ef20053638_ex2-1.htm.

International Money Express, Inc. Exhibit 99.1 to Form 8-K. U.S. Securities and Exchange Commission, 11 Aug. 2025, https://www.sec.gov/Archives/edgar/data/1683695/000114036125030254/ef20053740_ex99-1.htm.

International Money Express, Inc. Form 10-Q for the Quarterly Period Ended June 30, 2025. U.S. Securities and Exchange Commission, 11 Aug. 2025, https://www.sec.gov/Archives/edgar/data/1683695/000168369525000100/imxi-20250630.htm.

International Money Express, Inc. Form 8-K. U.S. Securities and Exchange Commission, 7 Oct. 2025, https://www.sec.gov/Archives/edgar/data/1683695/000114036125037505/ef20056756_8k.htm.

International Money Express, Inc. Form 10-Q for the Quarterly Period Ended September 30, 2025. U.S. Securities and Exchange Commission, Nov. 2025, https://www.sec.gov/Archives/edgar/data/1683695/000162828025051013/imxi-20250930.htm.

International Money Express, Inc. Form 8-K. U.S. Securities and Exchange Commission, 9 Dec. 2025, https://www.sec.gov/Archives/edgar/data/1683695/000114036125044991/ef20060920_8k.htm.

International Money Express, Inc. Form 10-K for the Fiscal Year Ended December 31, 2025. U.S. Securities and Exchange Commission, Mar. 2026, https://www.sec.gov/Archives/edgar/data/1683695/000162828026015647/imxi-20251231.htm.

International Money Express, Inc. Form 10-Q for the Quarterly Period Ended June 30, 2026. U.S. Securities and Exchange Commission, 2026, https://www.sec.gov/Archives/edgar/data/1683695/000162828026055191/imxi-20260630.htm.

TKNO Works Cited

Alpha Teknova, Inc. Form 10-K for the Fiscal Year Ended December 31, 2024. U.S. Securities and Exchange Commission, Mar. 2025, https://www.sec.gov/Archives/edgar/data/1850902/000095017025035705/tkno-20241231.htm.

Alpha Teknova, Inc. Common Stock Sales Agreement with Cowen and Company, LLC. U.S. Securities and Exchange Commission, 30 Mar. 2023, https://www.sec.gov/Archives/edgar/data/1850902/000095017023010926/tkno-ex1_1.htm.

Alpha Teknova, Inc. Limited Waiver and Amendment No. 5 to Amended and Restated Credit and Security Agreement, Term Loan. U.S. Securities and Exchange Commission, 8 Mar. 2024, https://www.sec.gov/Archives/edgar/data/1850902/000095017024029226/tkno-ex10_1.htm.

Alpha Teknova, Inc. Limited Waiver and Amendment No. 5 to Amended and Restated Credit and Security Agreement, Revolving Loan. U.S. Securities and Exchange Commission, 8 Mar. 2024, https://www.sec.gov/Archives/edgar/data/1850902/000095017024029226/tkno-ex10_2.htm.

Alpha Teknova, Inc. Second Amended and Restated Credit and Security Agreement, Term Loan. U.S. Securities and Exchange Commission, 3 Mar. 2025, https://www.sec.gov/Archives/edgar/data/1850902/000095017025031995/tkno-ex10_1.htm.

Alpha Teknova, Inc. Second Amended and Restated Credit and Security Agreement, Revolving Loan. U.S. Securities and Exchange Commission, 3 Mar. 2025, https://www.sec.gov/Archives/edgar/data/1850902/000095017025031995/tkno-ex10_2.htm.

Alpha Teknova, Inc. Exhibit 99.1 to Form 8-K: Teknova Reports First Quarter 2025 Financial Results. U.S. Securities and Exchange Commission, 8 May 2025, https://www.sec.gov/Archives/edgar/data/1850902/000095017025067005/tkno-ex99_1.htm.

Alpha Teknova, Inc. Form 10-Q for the Quarterly Period Ended March 31, 2025. U.S. Securities and Exchange Commission, May 2025, https://www.sec.gov/Archives/edgar/data/1850902/000095017025068050/tkno-20250331.htm.

Alpha Teknova, Inc. Exhibit 99.1 to Form 8-K: Teknova Reports Second Quarter 2025 Financial Results. U.S. Securities and Exchange Commission, 7 Aug. 2025, https://www.sec.gov/Archives/edgar/data/1850902/000095017025105005/tkno-ex99_1.htm.

Alpha Teknova, Inc. Form 10-Q for the Quarterly Period Ended June 30, 2025. U.S. Securities and Exchange Commission, Aug. 2025, https://www.sec.gov/Archives/edgar/data/1850902/000095017025105825/tkno-20250630.htm.

Alpha Teknova, Inc. Exhibit 99.1 to Form 8-K: Teknova Reports Third Quarter 2025 Financial Results. U.S. Securities and Exchange Commission, 6 Nov. 2025, https://www.sec.gov/Archives/edgar/data/1850902/000119312525269488/tkno-ex99_1.htm.

Alpha Teknova, Inc. Form 10-K for the Fiscal Year Ended December 31, 2025. U.S. Securities and Exchange Commission, 2 Mar. 2026, https://www.sec.gov/Archives/edgar/data/1850902/000185090226000002/tkno-20251231.htm.

Alpha Teknova, Inc. Exhibit 99.1 to Form 8-K: Teknova Reports First Quarter 2026 Financial Results. U.S. Securities and Exchange Commission, 6 May 2026, https://www.sec.gov/Archives/edgar/data/1850902/000185090226000007/tkno-ex99_1.htm.

Alpha Teknova, Inc. Form 10-Q for the Quarterly Period Ended March 31, 2026. U.S. Securities and Exchange Commission, May 2026, https://www.sec.gov/Archives/edgar/data/1850902/000185090226000008/tkno-20260331.htm.

ZNTL Works Cited

Zentalis Pharmaceuticals, Inc. Form 10-K for the Fiscal Year Ended December 31, 2025. U.S. Securities and Exchange Commission, Mar. 2026, Accession No. 0001725160-26-000014, https://www.sec.gov/Archives/edgar/data/1725160/000172516026000014/zntl-20251231.htm.

Zentalis Pharmaceuticals, Inc. Corporate Presentation. U.S. Securities and Exchange Commission, Jan. 2026, https://www.sec.gov/Archives/edgar/data/1725160/000172516026000003/zntlcorporatepresentatio.htm.

Zentalis Pharmaceuticals, Inc. Form 8-K. U.S. Securities and Exchange Commission, 9 Apr. 2026, Accession No. 0001725160-26-000017, https://www.sec.gov/Archives/edgar/data/1725160/000172516026000017/zntl-20260409.htm.

Zentalis Pharmaceuticals, Inc. Exhibit 99.1 to Form 8-K: April 2026 Corporate Presentation. U.S. Securities and Exchange Commission, 9 Apr. 2026, https://www.sec.gov/Archives/edgar/data/1725160/000172516026000017/ex991-zntlcorporateprese.htm.

Zentalis Pharmaceuticals, Inc. Exhibit 99.2 to Form 8-K: Dose Confirmation Press Release. U.S. Securities and Exchange Commission, 9 Apr. 2026, https://www.sec.gov/Archives/edgar/data/1725160/000172516026000017/ex992doseconfirmationpress.htm.

Zentalis Pharmaceuticals, Inc. Form 8-K: ASPENOVA First Patient Dosed. U.S. Securities and Exchange Commission, 5 May 2026, Accession No. 0001725160-26-000033, https://www.sec.gov/Archives/edgar/data/1725160/000172516026000033/zntl-20260505.htm.

Zentalis Pharmaceuticals, Inc. Q1 2026 Earnings Press Release. U.S. Securities and Exchange Commission, 12 May 2026, https://www.sec.gov/Archives/edgar/data/1725160/000172516026000041/zntlq12026pressrelease.htm.

Zentalis Pharmaceuticals, Inc. Corporate Presentation, May 2026. U.S. Securities and Exchange Commission, 12 May 2026, https://www.sec.gov/Archives/edgar/data/1725160/000172516026000041/zntlq12026corporatedeck.htm.

Zentalis Pharmaceuticals, Inc. Quarterly Report on Form 10-Q for the Quarter Ended March 31, 2026. U.S. Securities and Exchange Commission, May 2026, Accession No. 0001725160-26-000042, https://www.sec.gov/Archives/edgar/data/1725160/000172516026000042/zntl-20260331.htm.

KRMD Works Cited

KORU Medical Systems, Inc. Annual Report on Form 10-K for the Fiscal Year Ended December 31, 2025. U.S. Securities and Exchange Commission, 12 Mar. 2026, Accession No. 0001161697-26-000052, https://www.sec.gov/Archives/edgar/data/704440/000116169726000052/form_10-k.htm.

KORU Medical Systems, Inc. Exhibit 99.1: Fourth Quarter and Full Year 2025 Earnings Release and FY2026 Guidance. U.S. Securities and Exchange Commission, 12 Mar. 2026, Accession No. 0001161697-26-000051, https://www.sec.gov/Archives/edgar/data/704440/000116169726000051/ex_99-1.htm.

KORU Medical Systems, Inc. Form 8-K Current Report: Amendment No. 3 to Loan and Security Agreement with HSBC Ventures USA Inc. U.S. Securities and Exchange Commission, 3 Apr. 2026, Accession No. 0001161697-26-000086, https://www.sec.gov/Archives/edgar/data/704440/000116169726000086/form_8-k.htm.

KORU Medical Systems, Inc. Exhibit 99.1: First Quarter 2026 Earnings Release. U.S. Securities and Exchange Commission, 6 May 2026, Accession No. 0001161697-26-000107, https://www.sec.gov/Archives/edgar/data/704440/000116169726000107/ex_99-1.htm.

KORU Medical Systems, Inc. Quarterly Report on Form 10-Q for the Quarter Ended March 31, 2026. U.S. Securities and Exchange Commission, 6 May 2026, Accession No. 0001161697-26-000108, https://www.sec.gov/Archives/edgar/data/704440/000116169726000108/form_10-q.htm.

KORU Medical Systems, Inc. Exhibit 10.1: Amended and Restated Manufacturing and Supply Agreement between KORU Medical Systems, Inc. and Command Medical Products, LLC. U.S. Securities and Exchange Commission, 25 Nov. 2025, Accession No. 0001161697-25-000426, https://www.sec.gov/Archives/edgar/data/704440/000116169725000426/ex_10-1.htm.

KORU Medical Systems, Inc. Form 8-K Current Report: CEO Succession and Executive Compensation Arrangements. U.S. Securities and Exchange Commission, 13 Mar. 2026, Accession No. 0001161697-26-000055, https://www.sec.gov/Archives/edgar/data/704440/000116169726000055/form_8-k.htm.

KORU Medical Systems, Inc. Exhibit 10.1: Separation and Transition Agreement and General Release between KORU Medical Systems, Inc. and Linda Tharby. U.S. Securities and Exchange Commission, 13 Mar. 2026, https://www.sec.gov/Archives/edgar/data/704440/000116169726000055/ex_10-1.htm.

KORU Medical Systems, Inc. Exhibit 10.2: Amended and Restated Employment Agreement between KORU Medical Systems, Inc. and Adam Kalbermatten. U.S. Securities and Exchange Commission, 13 Mar. 2026, https://www.sec.gov/Archives/edgar/data/704440/000116169726000055/ex_10-2.htm.

KORU Medical Systems, Inc. Exhibit 10.1: Amendment No. 1 to Amended and Restated Manufacturing and Supply Agreement between KORU Medical Systems, Inc. and Command Medical Products, LLC. U.S. Securities and Exchange Commission, 30 June 2026, Accession No. 0001161697-26-000139, https://www.sec.gov/Archives/edgar/data/704440/000116169726000139/ex_10-1.htm.

KORU Medical Systems, Inc. Exhibit 99.1: Second Quarter 2026 Earnings Release and Updated FY2026 Guidance. U.S. Securities and Exchange Commission, 5 Aug. 2026, Accession No. 0001161697-26-000188, https://www.sec.gov/Archives/edgar/data/704440/000116169726000188/ex_99-1.htm.